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Abstract
Objective
Oral hypoglycemic agents (OHAs) are highly effective in managing Type 2 diabetes if taken
appropriately. This study assessed adherence to OHAs among patients with Type 2 diabe-
tes and explored factors associated with adherence behaviour.
Research design and methods
Mixed methods were used comprising a cross-sectional study using the Arabic version of
the Morisky Medication Adherence Scale followed by semi-structured interviews using the
Theoretical Domain Framework to explore key determinants of adherence.
Results
The cross-sectional study included 395 patients of whom 40% achieved a high level of OHA
adherence. Lower adherence was associated with younger age (Odds Ratio (OR) 1.084;
95% CI 1.056 to 1.112), higher numbers of non-OHAs (OR 0.848; 95% CI 0.728 to 0.986)
and higher HbA1c levels (OR 0.808; 95% CI 0.691 to 0.943). Semi structured interviews
based on the Theoretical Domain Framework were completed with 20 patients and identified
a wide range of factors potentially associated with OHA adherence, particularly behavioural
related factors (e.g. scheduling medication intake, ability to develop a habitual behaviour),
social influences (e.g. acting as a role model, the effect of family support), and gaps in
knowledge about diabetes and its management with OHAs.
Conclusions
This unique mixed-methods study has highlighted possible reasons for the low levels of
OHA adherence in this patient population. Whilst the theoretically-derived determinants of
behaviour illustrate the complexities associated with OHA adherence, they also provide a
robust underpinning for future intervention(s) development to improve adherence and maxi-
mise patient health outcomes.
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Introduction
Oral hypoglycemic agents (OHAs) are highly effective in managing Type 2 diabetes if taken
appropriately [1]. Adherence is defined by the World Health Organisation (WHO) as “the
extent to which a person’s behaviour–taking medication, following diet, and/or executing life-
style changes, corresponds with agreed recommendations from a health care provider” [1].
Adherence to diabetes medications is an important factor in achieving good diabetes control
and preventing mortality and morbidity [2]. It has been reported that adherence to OHAs var-
ies between 36% and 93% among different populations [3]. There are various methods to
assess medication adherence, of which, the Morisky Medication Adherence Scale (MMAS-8)
is a widely used self-administered validated tool [4].
Medication adherence is a complex process and is affected by diverse and multiple factors
[2]. A meta-analysis of 569 studies identified more than 200 variables associated with medica-
tion adherence behaviour [2]. Therefore using a comprehensive analytical approach to better
understand the particular barriers to and facilitators of adherence to therapy, is urgently
needed.
Saudi Arabia is facing an unprecedented increase in Type 2 diabetes and has one of the
highest prevalence rates i.e. 17.6%, in the world with high rates of chronic complications [5].
Although several studies have reported poor glycemic control as a significant factor behind
high complication rates, no studies have explored the low OHA adherence is a contributing
factor for such poor control in this national population [6]. Therefore, the Medication Adher-
ence in Saudi Arabia (MASA) Study is the first study in Saudi Arabia to assess adherence to
OHAs among participants with Type 2 diabetes who are not using insulin and to use a com-
prehensive framework of theoretical underpinning to explore the factors associated with
adherence behaviour.
Research design and methods
A sequential, explanatory mixed methods approach was used comprising a cross-sectional
study followed by theoretically-underpinned semi-structured interviews.
Cross-sectional study
Participants were recruited from the University Diabetes Centre (UDC), King Saud University,
Riyadh, Saudi Arabia. The UDC provides a five-day educational programme to their patients
with diabetes and closely monitors selected patients on a daily basis through a home blood glu-
cose monitoring programme (HBGM). Eligible participants were patients aged�18 years with
confirmed Type 2 diabetes for the past 12 months, who were receiving at least one OHA for 12
months prior to recruitment. Pregnant women, insulin users, participants with hearing or cog-
nitive impairment and non-Arabic speakers were excluded. A nurse screened participants by
applying the selection criteria to each individual’s medical record when attending their
appointment at the general diabetic clinic of the UDC. If eligible, the participants were invited
to participate and directed to talk to the researcher (NMA). The researcher then re-checked
the eligibility and provided further information about the study, including the information
sheet. participants provided signed consent if they agreed to participate. The Arabic version of
the MMAS-8 was used to calculate OHA adherence [4]. The Arabic version had some gram-
matical errors and corrections were undertaken. The corrected Arabic MMAS-8 version was
sent to Professor Donald Morisky to ensure the integrity of the Arabic MMAS-8 version for
the comparison of future results and he agreed to its use.
Data were collected through a chart review using a pre-designed data collection form that
consisted of two parts. Part 1 included socio-demographic characteristics: age; gender; marital
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status; income; and education. This part also included the diabetes history, all medications
being used and the individual’s Body Mass Index (BMI). The Medication Regimen Complexity
Score (MRCI) [6] was calculated for each participant as it was suggested as one of the factors
that affect medication adherence. Part 2 of the data collection form included the self-adminis-
tered MMAS-8. The data collection tool and process was piloted with 32 participants recruited
from the UDC clinic. The data from the participants of the pilot study were not used in the
final analysis.
The sample size for the MASA-8 study was derived from the results of an earlier study of
1367 participants in the United States [4] which reported high adherence (MMAS = 8) for
15.9% of participants. Assuming a high adherence rate of 15.9%, 400 participants would be
needed to estimate this proportion with an accuracy of ± 3.6%, i.e. with a 95% confidence
interval of 12.3% to 19.5%.
Semi-structured interview study
The interview study was conducted to explore barriers to and facilitators of OHA adherence.
Purposive sampling was used to derive a maximum variation sample of individuals with differ-
ent levels of adherence, as well as achieving a representative gender-age mix.
The topic guide was developed using the Theoretical Domain Framework (TDF) which
comprises 14 domains proven to be relevant to behaviour and behaviour enactment i.e. any
type of behaviour, not solely medication adherence [7,8]. Generic questions proposed to target
each of the TDF domains were modified to reflect the topic of interest; participants with Type
2 diabetes and medication adherence in Saudi Arabia. The topic guide was initially developed
in English (S1) and later translated into Arabic. It was reviewed by two bilingual professionals
(Arabic/English) and piloted with two Saudi participants with Type 2 diabetes in order to
assess its clarity and consistency. The interviews were conducted face-to-face, audio-recorded
and transcribed verbatim. participants were interviewed until data saturation was achieved
and no new codes emerged. Ethical approval was given by the Institutional Review Board
(IRB) of the Medical College of King Saud University (E-13-1058) where the participants were
recruited, and the College Ethical Review Board (CERB), University of Aberdeen (CERB/
2014/1/975). The Strengthening the Reporting of Observational Studies in Epidemiology State-
ment (STROBE) [9] for reporting cross-sectional studies and the Consolidated Criteria for
Reporting Qualitative Research (COREQ) checklists [10] were followed in the reporting of this
study (S3 Table).
Analysis
Data from the cross-sectional study were analysed using Statistical Package for the Social Sci-
ences (SPSS) version 22. Descriptive statistics were used to summarise participants’ demo-
graphics and MMAS-8 scores. A MMAS-8 score of 8 was defined as high adherence, 6�
MMAS <8 as moderate adherence, and a score <6 as low adherence. Ordinal logistic regres-
sion was used to predict the association of OHA adherence category with socio-demographic
and clinical factors.
Thematic content analysis was undertaken during which the interview transcripts were ana-
lysed systematically. First, two interviews were undertaken, transcribed into Arabic and trans-
lated to English. The two interviews were analysed independently by authors NMA and VA-S
to code for barriers and facilitators to OHA adherence. Next, a further five interviews were
transcribed in Arabic and analysed by NMA using the draft coding manual developed from
the first two interviews. Additional codes emerged and were linked to the appropriate TDF
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domains. All quotations selected, and related codes, were translated to English and discussed
with VA-S.
The final coding manual with definitions was agreed upon and used for all subsequent
interviews. NMA analysed the remaining interviews. Authors NMA and HSA discussed the
quotations in Arabic and their related codes and selected the quotations presented.
All the above steps were conducted independently by a minimum of two researchers to
maximize validity. Disagreements were resolved by discussion. NVivo 10 for Windows was
used to support the analysis of the first two interviews. NVivo 10 has, however, some limita-
tions as it does not support the Arabic language and therefore could not be used to analyse the
remaining interviews. ATLAS.ti 7 worked well and presented fewer problems than NVivo 10.
ATLAS.ti 7 was therefore used to support the analysis of the remaining interviews.
Results
In total, 395 patients participated in the cross-sectional study which was conducted between
May and October 2014. The mean (SD) age was 57.8 (8.7) years, the majority were male and
were married. The participant’s mean (SD) duration of diabetes was 12.9 (8.0) years and their
mean (SD) HbA1c was 7.9% (1.4) or 63 (15.3) mmol/mol. The mean (SD) BMI was 30.5 (6.0)
kg/m2.
The mean (SD) number of OHAs was 1.7 (0.7) and the mean (SD) duration of OHA use
was 11.8 (7.4) years. More than 40% of the studied cohort were college graduates or higher and
more than 30% had a monthly income of less than 10,000 Saudi Riyals (SR) ($2666),
(1SR = 0.27 USD) (Table 1).
High (MMAS = 8) levels of OHA adherence were reported in 40% (n = 158), moderate (6�
MMAS <8) levels with 37% (n = 145) and low (MMAS <6) adherence with 23% (n = 92).
Factors associated with OHA adherence
Higher levels of adherence were observed with increasing age (OR, 1.084; 95% CI, 1.056–
1.112), taking fewer non-diabetic medications (OR, 0.848; 95% CI, 0.728–0.986), and lower
HbA1c (OR, 0.808; 95% CI, 0.691–0.943) (Table 2). There was no evidence that the other
parameters tested (gender, marital status, education level, income and diabetes duration) were
associated with OHA adherence.
Key factors associated with adherence to OHAs
Half of the participants included in the cross-sectional study (n = 199) were invited to partici-
pate in an interview and 54% (n = 108) of them agreed to be interviewed and provided the
researcher with their contact details. A list was created that contained the study ID, name, gen-
der, age, adherence level and contact information of the participants who agreed to be inter-
viewed. Then, they were sampled purposively according to the required characteristics
following the sequence of the list. Interviews were completed with 20 individuals. Patients
were interviewed until data saturation was achieved and no new codes emerged. Data satura-
tion was reached with 17 interviewees and three additional interviews were conducted for
assurance. The mean age and range of the included sample was 51.4 (range 26–72) years and
55% of the sample were men with a mean diabetes duration at 11.7 (range 3–20) years, and
mean HbA1c of 8% (range 6.9–13.3) or 64 (range 78.1–47.5) mmol/mol (S2 Table).
Thematic content analysis was performed, which involved systematically analysing tran-
scripts, assigning codes to particular ideas (data) and gathering together examples of those
codes from the text. Several cycles of coding were needed to reach the final version of the cod-
ing manual. For example, the number of codes at the first stage of the analysis was 104, but
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decreased to 65 and then to 36 in subsequent stages. The codes that emerged were linked back
to the domains of the TDF for helping in future mapping of intervention(s). For example, if a
patient was described lack of knowledge of the side effects of his/her diabetic medication, this
was coded as "knowledge of OHM" and linked to the TDF "knowledge" domain. Similarly, if
the patient talked about the role of his/her spouse in reminding him/her to take his medication
this was coded as "family support" and linked to the "social influence" domain. The interview
results revealed various factors associated with OHA adherence which were clustered around
13 of the 14 TDF domains. The only domain that was not coded on this sample was the
“Goals” domain. Table 3 presents the factors identified and example quotations linked to the
TDF domains. Each quotation is referenced with the participants study ID, age, gender, adher-
ence and HbA1c levels. Six domains were of particular relevance: behavioural regulation, social
influence, knowledge, environmental context, beliefs about diabetes consequences and mem-
ory attention and these are presented in more detail below.
In the domain behavioural regulation it emerged that scheduling medication intake and the
ability to develop a habitual behaviour were facilitators for OHA adherence.
Table 1. Characteristics of participants in the cross sectional study n = 395.
Characteristics Category Subcategory MMAS-8 adherence score
Total High = 8 Moderate <8 to 6 Low <6
Number (%) 395 (100) 158 (40.0) 145 (36.7) 92 (23.3)
Age (years) mean (SD) 57.8 (10.7) 62.0 (9.7) 56.9 (9.2) 52.0 (11.4)
BMI (kg/m2) mean (SD) 30.5 (6.0) 30.1 (6.2) 31.1 (6.1) 30.3 (5.5)
Duration of diabetes mean (SD) 12.9 (8.0) 14.7 (8.4) 12.4 (7.8) 10.7 (6.9)
Number of OHM taken mean (SD) 1.7 (0.7) 1.7 (0.7) 1.8 (0.7) 1.7 (0.6)
Duration of OHM use (years) mean (SD) 11.8 (7.4) 13.6 (7.7) 11.4 (7.1) 9.5 (6.5)
Number of other medication used mean (SD) 4.1 (2.3) 4.2 (1.9) 4.2 (2.6) 3.7 (2.4)
HbA1c mean (SD) 7.9 (1.4) 7.8 (1.3) 7.9 (1.2) 8.3 (1.7)
MRCI mean (SD) 11.0 (4.0) 11.1 (3.5) 11.1 (4.3) 10.6 (4.4)
Five-day educational programme (%) 203 (51.4) 79 (50.0) 70 (48.3) 54 (58.7)
Enrolled with HBGM (%) No 269 (68.1) 110 (69.7) 101 (69.7) 58 (63.0)
Yes, before 91 (23.0) 36 (22.8) 30 (20.7) 25 (27.2)
Yes, now 35 (8.9) 36 (22.8) 30 (20.7) 25 (27.2)
Gender Men (%) 236 (59.7) 105 (44.5) 78 (33.1) 53 (22.4)
Women (%) 159 (40.3) 53 (33.3) 67 (42.1) 39 (22.6)
Education (%) No 71 (18.0) 33 (20.9) 23 (15.9) 15 (16.3)
High school or lower 149 (37.7) 56 (35.4) 61 (42.1) 32 (34.8)
College or higher 175 (44.3) 69 (43.7) 61 (42.1) 45 (48.9)
Marital status (%) Married 344 (87.1) 137 (86.7) 128 (88.3) 79 (85.9)
Single� 51 (12.9) 21 (41.2) 17 (33.3) 13 (25.5)
Income (SR) (%) <5000 53 (13.4) 20 (13.4) 19 (13.6) 14 (15.4)
>5000–10000 74 (18.7) 37 (24.8) 22 (15.7) 15 (16.5)
10000–20000 153 (38.7) 58 (38.9) 62 (44.3) 33 (36.3)
20000–35000 60 (15.2) 16 (10.7) 27 (19.3) 17 (18.7)
>35000 40 (10.1) 18 (12.1) 10 (7.1) 12 (13.2)
BMI, body mass index; CI, confidence interval; HbA1c, glycosylated haemoglobin; HBGM, home blood glucose monitoring; MMAS, Morisky Medication Adherence
Score; MRCI, Medication Regimen Complexity Index (higher score represent higher complexity); OHM, Oral Hypoglycaemic Medication; SD, standard deviation; SR,
Saudi Riyals (1 SR = $0.27)
� includes unmarried, divorced and widow.
https://doi.org/10.1371/journal.pone.0207583.t001
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Table 2. Factors predicting OHM adherence using ordinal logistic regression analysis.
Category Subcategory OR (95% CI) P value
Age (years) 1.084 (1.056–
1.112)
<0.001
Gender Women 1 -
Men 0.753 (0.467–
1.215)
0.060
Marital status Married 1 -
Single 1.128 (0.539–
2.361)
0.750
Education No 1 -
High school or
lower
0.485 (0.224–
1.050)
0.067
College or higher 0.841 (0.506–
1.396)
0.503
Income (SR) �5000 1 -
>5000–10000 2.241 (0.850–
5.907)
0.103
>10000–20000 2.139 (0.938–
4.879)
0.071
>20000–35000 1.404 (0.697–
2.825)
0.342
>35000 0.833 (0.379–
1.830)
0.649
BMI (kg/m2) N = 394� 1.036 (0.999–
1.074)
0.060
Duration of diabetes (years) 1.022 (0.953–
1.096)
0.539
HbA1c (%) 0.808 (0.691–
0.943)
0.007
Number of OHM taken 0.818 (0.564–
1.187)
0.290
Duration of OHM use (years) 1.019 (0.944–
1.100)
0.632
Number of other medication used 0.848 (0.728–
0.986)
0.032
Duration between HbA1c test and completion of MMAS-8
(days)
1.001 (0.991–
1.011)
0.800
MRCI 1.017 (0934–
1.108)
0.698
Completed the five-day educational programme No 1 -
Yes 1.089 (0.716–
1.657)
0.691
Enrolled with HBGM No 1 -
Yes, before 0.916 (0.444–
1.892)
0.813
Yes, now 0.916 (0.413–
2.035)
0.830
The bold values represent statistically significant differences (P<0.05).
BMI, body mass index; CI, confidence interval; HbA1c, glycosylated haemoglobin; HBGM; home blood glucose
monitoring; MMAS, Morisky Medication Adherence Score; MRCI, medication regimen complexity index (higher
score represent higher complexity); OHM, Oral Hypoglycaemic Medication; SR, Saudi Riyals (1 SR = $0.27).
�missing BMI information for one participant.
https://doi.org/10.1371/journal.pone.0207583.t002
Medication adherence in patients with Type 2 diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0207583 December 11, 2018 6 / 18
Table 3. Domains from the TDF and example quotes for barriers and facilitators of adherence behaviour.
TDF Domain Facilitator of adherence Barrier to adherence
Behavioural Regulation Scheduling medication intake
“Yes, I rarely forget it; I have one box divided into two places. I’m
carrying inside it my diabetes and blood pressure pills.” MASA 143,
M, 37 years, MMAS 3.5, HbA1c 6.9%.
Being able to develop a habitual/automatic behaviour
“In the first 1 to 3 years it’s a big deal, but after 15 years it became a
habit, just like smoking; if I eat and don’t take it I think, “Where is
the medication? Bring me the medication” ID 125, M, 61 years
MMAS 7, HbA1c 8.4%.
Experience of managing hypoglycaemia
“I have my own device and the hospital gave me a device and chips
so I kept checking the diabetes. I noticed that everything is fine, and
that is it [the reason to discontinue the OHM]” ID 143, M, 37 years,
MMAS 3.5, HbA1c 6.9%.
Social Influences The effect of family support
“. . .. if I reject the medications and don’t want to take them, the
doctor would speak to my husband or my brother and say take care
of her, take her to a shrink, maybe there is some pressure at home,
maybe there are problems. . ..” MASA 186, F, 41 years, MMAS 2.5,
HbA1c 7.5%.
Sharing medication (in case of forgetfulness and/or before collecting
a prescription)
“I once attended an event and the host [a friend] prepared a plate full
of Glucophage [OHM] and said if anyone forgot to take it, here it is
on the plate, out of hospitality.” ID 019, M, 49 years, MMAS 8,
HbA1c 8%.
Having a supportive physician
“I try to memorise the medication name so when I talk to the doctor
he understands me . . ., and this gives him more confidence; when he
has confidence in me I have confidence in him too . . . and that is a
connection between us”MASA 125, M, 61 years, MMAS 7, HbA1c
8.4%.
Acting as a role model
“At gatherings I say bring me my medicine to take away shame from
the others. . .if those who hold college degree and also say bring me
my medicine. . .” ID 166, M, 55 years, MMAS 8, HbA1c 7.5%.
Family gatherings and holidays
“I have to attend family gatherings, which creates pressure on me. I
don’t like when people start asking me what medication I’m taking
or what’s wrong with me.” ID 186, F, 41 years, MMAS 2.5, HbA1c
7.5%
Physician–patient relationships
“. . ., the first doctor wasn’t good.. you tell him that you feel dizzy,
and he says don’t stop the medication. I didn’t go to him again and I
keep monitoring myself. I decided that I will never go again. . ...”. ID
78, M, 26 yeas, MMAS 2.5, HbA1c 7%.
Knowledge Observing a family member’s suffering from diabetic complications
because of not adhering to the diabetic medication
“Why should I commit [to take OHM], because I lived through a
tragedy. . . .. He [his father] got diabetic gangrene which required
that one of his limbs be cut off. This horrified us, and later I
discovered by chance that I have diabetes” ID 019, M, 49 years,
MMAS 8, HbA1c 8%.
Provide knowledge on diabetes to their own families
“If there is something to raise awareness, if there is supportive
medication, at least some brochures to educate my wife [about
sexual health]. . ..” MASA 019, M, 49 years, MMAS 8, HbA1c 8%.
Education about OHM, particularly on the medication’s mechanism
of action, side effects, and interactions with other drugs
“When you take a medicine and you have no idea what it does.. you
just take it, . . .. but when someone tells you all this [about OHM]
you become able to notice any change in your body and how to
handle it.. you know when routines or food changes... . ..” MASA
125, M, 61 years, MMAS 7, HbA1c 8.4%.
Education about medication adherence issues “The UDC gave us
two lectures about the medications, they taught us what is the name
of the medication and other related information . . .They should give
us tips to motivate ourselves to take the medication not only the
information about the medication” MASA 110, M, 33 years, MMAS
3.75, HbA1c 7.7%.
Knowledge about managing OHM when changes in routines occur
“. . . yesterday I took my medication but I didn’t have an appetite for
dinner. . . so I ate a cheesecake, . . . the pharmacy gave you the
medication and they do not know you, you have to know yourself
. . ...” MASA 110, M, 33 years, MMAS 3.75, HbA1c 7.7%.
(Continued)
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Table 3. (Continued)
TDF Domain Facilitator of adherence Barrier to adherence
Environmental context
and resources
Having trust in the UDC and having appropriate follow-up
“(. . .). first of all, after the visits there should be connection through
the phone on a weekly basis to check on the patient’s condition, just
to make sure that the patient doesn’t stop taking his medications”
MASA 186, F, 41 years, MMAS 2.5, HbA1c 7.5%.
Being able to have access to medication without a prescription
“. . . I take enough depending on the period I am travelling. If it runs
out I get it from the pharmacy, as I already know the name of the
medicine. .” ID 125, M, 61 years, MMAS 7, HbA1c 8.4%.
Impact of Saudi culture such as religious beliefs, activities, and
dedication on OHM adherence.
“I take my medicine because it’s a way to worship Allah, because he
says don’t throw yourselves in Tahluka [anything that would lead to
your death].” ID 166, M, 55 years, MMAS 8, HbA1c 7.5%.
Stress
“. . .I do not want anything to restrict me. If I wasn’t afraid of the
diabetes worsening I would stop the regulator [Glucophage, an
OHM] also [she stopped all her medication except OHM].” MASA
186, F, 41 years, MMAS 2.5, HbA1c 7.5%.
Having to manage the multiple intake of several medications
“I would like to take one pill instead of two; it has the same medical
effect but it makes me feel better”MASA 110, M, 33 years, MMAS
3.75, HbA1c 7.7%.
The pharmacy service at the UDC.
“. . . This is one of the obstacles; sometimes I need to travel for a
conference or a meeting and my medications are about to run out
but I still didn’t finish my three months. They would say we can give
it to you five days earlier, but no more than this..!” MASA 006, M, 44
years, MMAS 7, HbA1c 7.4%.
Experiencing a hypoglycaemic incident.
“. . . there was an accident .. A person took the wrong side of the
road. . . we came face to face; I avoided him but the driver on my
right couldn’t and they crashed face to face and he died immediately.
. . . they said that .. he had a diabetic attack. It would be a disaster if I
have one while driving.” MASA 143, M, 37 years, MMAS 3.5, HbA1c
6.9%.
Beliefs about
consequences
Avoiding diabetic complications
“.. I’m afraid the complications can affect the kidneys and eyes.
. . .I’m terrified; I would like to ask how I can prevent it from
affecting my legs and kidneys.” MASA 168, F, 44 years, MMAS 6,
HbA1c 8.8%.
Side effects of OHM
”. . . I suffer from diabetes and obesity, and these medications
contradict what I do, so they did not do me any good and I stopped
taking them.” MASA 125, M, 61 years, MMAS 7, HbA1c 8.4%.
Not feeling any symptoms of diabetes
“I didn’t take it [the OHM] for six months and didn’t feel anything,
and when I took it I didn’t feel anything. When I took it I never felt
anything, and even when I didn’t take it I felt the same” ID 196, M,
63 years, MMAS 3, HbA1c 13.3%.
Feeling improved quality of life
“No, Alhamdulillah (thank God) I became better; I felt some muscle
ache but now it is gone since I started taking the diabetes pills”
MASA 184, F, 64 years, MMAS 7, HbA1c 8.7%.
Avoiding being prescribed insulin injections
“It was a turning point in my life when the doctor said that if the pills
don’t work we will have to initiate injections. . . it made me think I
don’t want to take injections for the rest of my life. You can punish
me anyway but don’t give me injections.” ID 402, F, 58 years, MMAS
8, HbA1c 7%.
Memory, attention, and
decision processes
A decision to adhere to medication with improved quality of life.
“No, Alhamdulillah (thank God) I became better; I felt some muscle
ache but now it is gone since I started taking the diabetes pills”
MASA 184, F, 64 years, MMAS 7, HbA1c 8.7%.
Forgetfulness
“What can I do? I overslept. I don’t want to have dinner and I forgot
my dose. This happens to me once or twice a month.” ID 168, F, 44
years, MMAS 6, HbA1c 8.8%.
A decision of non-adherence was mentioned in association with
different domains such as stress, hypoglycaemic side effect
“. . .I do not want anything to restrict me. If I wasn’t afraid of the
diabetes worsening I would stop the regulator [Glucophage, an
OHM] also [she stopped all her medication except OHM].” MASA
186, F, 41 years, MMAS 2.5, HbA1c 7.5%.
”. . . I suffer from diabetes and obesity, and these medications
contradict what I do, so they did not do me any good and I stopped
taking them.” ID 125, M, 61 years, MMAS 7, HbA1c 8.4%.
(Continued)
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Table 3. (Continued)
TDF Domain Facilitator of adherence Barrier to adherence
Optimism Awareness of the importance of OHM in diabetes management
“Any medication you hate it . . . you cannot benefit from it.. Right?
But if you decide to accept it and focus on your inner psychological
acceptance everything will be fine” MASA 007, M, 66 years, MMAS
8, HbA1c 7.8%.
Interviewees adhere to OHM in the anticipation of better results
“Yes, I told you that I do not take the medications for the sake of
today; I take them for the sake of the future.” MASA 182, M, 41
years, MMAS 6.75, HbA1c 7.2%
Long-term use of OHM was associated with an optimistic belief of
eventually being off the medication
“I wish I could reach the point where I can control it with diet
only. . . no medication” MASA 402, F, 58 years, MMAS 8, HbA1c
7%.
Emotion Positive emotions
“I used to feel that my body is very heavy, buy when I monitored my
diabetes and take my pills I felt more active, lively, and youthful. . ..
You live happily, you feel like you can do anything, you sleep happily,
and you’re happy with your family. MASA 402, F, 58 years, MMAS 8,
HbA1c 7%.
Worry
“Maybe I’m very careful. I want to decrease anxiety; I do not want to
leave my medicine, but I do not want to focus too much, and I
wonder if I’ve taken the pill. It’s my nature and it’s reflected on my
medications.” MASA 168, F, 44 years, MMAS 6, HbA1c 8.8%.
Frustration
“As I’m a teacher, I have to wake up and eat my breakfast in the early
morning. Some days I do not have an appetite but I have to force
myself to eat in order to take my diabetic pills, which is really
frustrating. . . and again at the dinner time I suffered also, because
most of the times I force myself to eat just to take the medication.. I
wish I was like normal people where I eat when I feel to and want to
. . .” MASA 168, F, 44 years, MMAS 6, HbA1c 8.8%.
Boredom
“Honestly, I am bored of medications. I would like something that I
could take once and that is it.” MASA 78, M, 26 years, MMAS 2.5,
HbA1c 7%.
Beliefs about capabilities OHM adherence as an easy behaviour to achieve.
“To cut it short, there is no hardship in taking medicine.” MASA 169,
M, 47 years, MMAS 8, HbA1c 7%.
Self-confidence helped with OHM adherence.
“Deep inside me I’m confident of myself and I know that it’s
dangerous for me to stop it [OHM]. It’s not only dangerous; the pain
will increase and everything else will increase.” MASA 65, F, 64 years,
MMAS 8, HbA1c 8.2%.
10. Reinforcement Self-reward or taking one day off per week to eat sweets.
“I always think of giving gifts to myself if I take my medication and
controlled my sugar, like a grilled fish in the highest quality
restaurant, or buying a new shemagh [Saudi men head cover] or
besht [Saudi men clothing] just like I’m giving a gift to my wife or
children. . .” MASA 166, M, 55 years, MMAS 8, HbA1c 7.5%.
Encouraging letters or certificates from the UDC to the patients.
“Why do not give a certificate from the UDC to my family. . . just like
we do at the school, when I gave certificate to the student’s mother
thanking her daughter performance, the daughter improves even
more. . .it will cost nothing but I think it will support us” MASA 186,
F, 41 years, MMAS 2.5, HbA1c 7.5.
Monthly appointments with a dietician and close contact and
support from the diabetic clinic.
“There are moral [He means not material] incentives. I used to go to
a dietician, and the appointment was every two weeks. I used to
consider myself a challenge to the doctor, a case that didn’t lose
weight sometimes. Sometimes she would get angry with me and that
give me push to work harder.” MASA 110, M, 33 years, MMAS 3.75,
HbA1c 7.7%.
(Continued)
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“In the first 1 to 3 years it’s a big deal, but after 15 years it became a habit, just like smoking; if
I eat and don’t take it I think, “Where is the medication? Bring me the medication” ID 125,
M, 61 years MMAS 7, HbA1c 8.4%.
Unexpectedly, blood glucose monitoring and managing hypoglycemic were reported to be
the barriers to OHA adherence.
“I have my own device and the hospital gave me a device and chips so I kept checking the dia-
betes. I noticed that everything is fine, and that is it [the reason to discontinue the OHM]” ID
143, M, 37 years, MMAS 3.5, HbA1c 6.9%.
When examining the factors related to the social influence domain, acting as a role model,
the effect of family support, sharing medication at social events (with companions who had
forgotten their OHAs) and having a supportive physician, were the main facilitators associated
with OHA adherence.
“At gatherings I say bring me my medicine to take away shame from the others. . .if those who
hold college degree and also say bring me my medicine. . .” ID 166, M, 55 years, MMAS 8,
HbA1c 7.5%.
“I once attended an event and the host [a friend] prepared a plate full of Glucophage [OHM]
and said if anyone forgot to take it, here it is on the plate, out of hospitality.” ID 019, M, 49
years, MMAS 8, HbA1c 8%.
Table 3. (Continued)
TDF Domain Facilitator of adherence Barrier to adherence
Skills Knowing when and how to take their OHM.
“[the question was how easy do you find taking diabetic medication]
. . .very easy thanks to Allah [God]” MASA 006, M, 44 years, MMAS
7, HbA1c 7.4%.
Practicing stress management techniques would help facing stress.
“When I take the medication, and I remember that I took blood
pressure medication also, I know that I do not want the pressure to
rise, or the diabetes to rise too. I’m trying to avoid problems as much
as I can.” MASA 125, M, 61 years, MMAS 7, HbA1c 8.4%.
Social/professional role
and identity
Interviewees who considered themselves as organized and
committed to their plans, are motivated to review their medication
and think about it like any other of their activities.
"Why I’m taking my medication. . ..? I do not have specific reasons..I
was always been a person who like organization, and arranging stuff
in their places.. even who visit me at my office they do not find even
a piece of paper on my desk!..even my car everybody see it as very
neat and organized" MASA 006, M, 44 years, MMAS 7, HbA1c 7.4%.
Intentions An intention to cure from diabetes
“My goal, God willing, is to recover [from diabetes] and stop the
medications.” MASA 007, M, 66 years, MMAS 8, HbA1c 7.8%.
To attain and/or preserve good quality of life and avoid severe
consequences to their health.
“In all of our programmes, we set a general aim and a specific aim.
The general aim is to preserve health; diabetes medications will be
with you all your life. The specific aim is that you can live each stage
with its good [he means good things in life], and this does not
happen unless you take your diabetes medications and follow the
doctor’s instruction.” MASA 006, M, 44 years, MMAS 7, HbA1c
7.4%.
https://doi.org/10.1371/journal.pone.0207583.t003
Medication adherence in patients with Type 2 diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0207583 December 11, 2018 10 / 18
Conversely, family gathering and holidays had detrimental effects on adherence.
“I have to attend family gatherings, which creates pressure on me. I don’t like when people
start asking me what medication I’m taking or what’s wrong with me.” ID 186, F, 41 years,
MMAS 2.5, HbA1c 7.5%
Furthermore, having a poor patient-physician relationship was perceived to have a deter-
mined effect on OHA adherence.
“. . ., the first doctor wasn’t good.. you tell him that you feel dizzy, and he says don’t stop the
medication. I didn’t go to him again and I keep monitoring myself. I decided that I will never
go again. . ...”. ID 78, M, 26 years, MMAS 2.5, HbA1c 7%.
Knowledge about diabetes and its management with OHAs influenced adherence and was
often related to access to information. For example, family members’ lack of knowledge about
the disease negatively impacted adherence, as did interviewee lack of information regarding
OHAs, adherence and relevant lifestyle behaviour. Furthermore, knowledge gained from
observing a family member’s suffering from diabetic complications because of not adhering to
the diabetic medication facilitated this participant to adhere to his medication.
“Why should I commit [to take OHM], because I lived through a tragedy. . . .. He [his father]
got diabetic gangrene which required that one of his limbs be cut off. This horrified us, and
later I discovered by chance that I have diabetes” ID 019, M, 49 years, MMAS 8, HbA1c 8%.
The environmental context and resources domain includes the availability of material and/or
social resources, to facilitate medication adherence. Factors identified were having trust in the
centre and appropriate follow-up. Access to OHAs in the community pharmacies without pre-
scription was considered to be a facilitator for OHA adherence.
“. . . I take enough depending on the period I am travelling. If it runs out I get it from the phar-
macy, as I already know the name of the medicine. .” ID 125, M, 61 years, MMAS 7, HbA1c
8.4%.
The environmental context and resources domain also included the effect of religious
beliefs on OHM adherence by increasing acceptance of the condition as well as of the medical
recommendations by following the physician’s instructions and maintaining the patients’ own
health.
“I take my medicine because it’s a way to worship Allah, because he says don’t throw your-
selves in Tahluka [anything that would lead to your death].” ID 166, M, 55 years, MMAS 8,
HbA1c 7.5%.
Conversely, psychosocial stress, witnessing accidents related to hypoglycemic events and
prescriptions refill barriers such as restricted date and or duration of refilling a prescription,
were identified as barriers to OHA adherence rel;ated to the environmental context and
resources domain.
Furthermore, having to manage the multiple intake of several medications was identified as
a barrier to OHA adherence related to the environmental context and resource domain.
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“I would like to take one pill instead of two; it has the same medical effect but it makes me feel
better”ID 110, M, 33 years, MMAS 3.75, HbA1c 7.7%.
Beliefs about consequences included consequences of having diabetes as well as conse-
quences of using OHAs. Improved quality of life and the avoidance of adverse health outcomes
and the need to use insulin, were factors which encouraged adherent behaviour.
“It was a turning point in my life when the doctor said that if the pills don’t work we will have
to initiate injections. . . it made me think I don’t want to take injections for the rest of my life.
You can punish me anyway but don’t give me injections.” ID 402, F, 58 years, MMAS 8,
HbA1c 7%.
“No, Alhamdulillah (thank God) I became better; I felt some muscle ache but now it is gone
since I started taking the diabetes pills” ID 184, F, 64 years, MMAS 7, HbA1c 8.7%.
However, fear of OHA side effects as well as being asymptomatic reduced adherence as the
following quotation illustrate.
“I didn’t take it [the OHM] for six months and didn’t feel anything, and when I took it I
didn’t feel anything. When I took it I never felt anything, and even when I didn’t take it I felt
the same” ID 196, M, 63 years, MMAS 3, HbA1c 13.3%.
The memory, attention and decision process domain was clearly facilitated by each partici-
pants’ personal decision to adhere to OHAs to improve his/her quality of life. On the other
hand, barriers to OHA adherence related to this domain were forgetfulness which interviewees
experienced because they were tired and their decision to OHA due to stress and hypoglycemic
side effects.
“What can I do? I overslept. I don’t want to have dinner and I forgot my dose. This happens to
me once or twice a month.” ID 168, F, 44 years, MMAS 6, HbA1c 8.8%.
”. . . I suffer from diabetes and obesity, and these medications contradict what I do, so they did
not do me any good and I stopped taking them.” ID 125, M, 61 years, MMAS 7, HbA1c 8.4%.
Discussion
Despite free medical services and medication in Saudi Arabia, good OHA adherence among
the studied cohort was low, i.e. 40%. This rate is lower than rates reported in India and Malay-
sia [11–13] but considerably higher than the 9% reported in the United Arab Emirates (UAE)
[14] (Table 4). The UAE cohort was recruited from primary health care centres rather than a
tertiary centre as in the current study, which may also have contributed to the difference in
prevalence. Whilst several studies have assessed OHA adherence in Saudi Arabia, none
focused on non-insulin users only [15–18]. Studies of Type 2 diabetic patients showed differ-
ent behaviour toward medication-taking than patients who were using insulin plus OHA, with
different adherence being associated with education and instruction provided to insulin users,
as well as fear of hypoglycaemia and injections [19]. This study synthesized high-quality evi-
dence about the level of OHA adherence in Type 2 diabetics who are not using insulin and
identified factors affecting OHA adherence in the Saudi population.
In terms of demographic and clinical factors the current study demonstrated older age to
be associated with better OHA adherence and this has been identified previously [11,14]. Low
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HbA1c was associated with better OHA adherence. The results of a recent systematic review
showed a significant negative correlation between OHA adherence and HbA1c irrespective of
the measure used [20]. However, it is to be noted that factors other than the level of OHA
adherence, such as following a healthy lifestyle might result in better HbA1c levels [21]. Poly-
pharmacy has previously been shown to be inversely associated with medication adherence [2]
and this was also reflected in the current study both for total number of OHAs used as well as
total number of medications (for any condition). Higher OHA adherence was associated with
using fewer OHAs and fewer medications in general. In the current study, this association was
not statistically significant for OHAs, possibly due to few multiple OHAs being used (Table 1).
Gender, education, marital status, income, BMI, diabetes duration, completion of diabetes
education program and enrollment in the home blood glucose monitoring were not statisti-
cally significant predictors of OHA adherence in the current study and reflects previous
research which failed to identify any consistent association between OHA adherence and
sociodemographic and disease factors [22].
Using a theory or theories in qualitative research design when attempting to increase
knowledge on a specific area is a form of saving time and effort by considering a set of key vari-
ables that have emerged as relevant for the explanation of the behaviour [8]. The results of the
MASA interview study derived from the TDF provide further depth and understanding to
those of the cross-sectional study, in terms of factors influencing OHA adherence. Several
studies conducted on Saudi participants have used qualitative measures to explore medication
taking behaviour but either did not used theoretical underpinning [23] or used only one theory
such as health belief model [24] or Modified Social Learning Theory [25].
Explaining behaviour and improving it through theory-based research has been used previ-
ously in medication adherence studies [26,27] but with limited benefit in changing targeted
behaviour, which might be due to the large pool of theories or a limited understanding of
which theory to choose and how to apply it to the problem studied [8]. The MASA Interview
Study used the TDF to explore OHA adherence. The use of the TDF that integrates 33 psycho-
logical theories to understand behaviour was applicable and useful [8]. The TDF identified
additional factors which illustrated that OHA adherence is a result of different interactions
between patient and other factors, which might explain why most of the interventions target-
ing medication adherence have not been successful. The following section discusses some of
these factors.
Table 4. Cross-country comparison of prevalence of medication adherence using MMAS-8.
Study Country N Morisky Medication Adherence Scale
Low
MMAS<6
(%)
Moderate
MMAS�6-<8 (%)
High
MMAS = 8 (%)
Al-Qazaz 2011 [12] Malaysia 540 Median (IQR) 6.5 (4.7–7.75) NA NA NA
Arulmozhi 2014 [11] India 150 Mean (SD) 6.6(2.0) 26.0 24.7 49.3
Manan 2014 [13] Malaysia 179 Median (IQR) 7.8 (6.5–8.0) 52.0 48.0
Al-Haj Mohd 2016 [14] United Arab Emirates 446 NA 64.57 26.46 8.97
Aloudah NM (Current study) Saudi Arabia 395 Median (IQR) 7.0 (6.0–8.0) 23.3 36.7 40.0
23.3 76.7
60.0 40.0
IQR; interquartile range, MMAS, Morisky Medication Adherence Score, NA; not applicable, SD; standard deviation.
https://doi.org/10.1371/journal.pone.0207583.t004
Medication adherence in patients with Type 2 diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0207583 December 11, 2018 13 / 18
The interviewees expressed a need for building the habit of OHA adherence and this reflects
studies with Canadians [28] and Turkish migrants [29], which demonstrated the importance
of daily routine as well as being able to modify medication use in accordance with food intake.
Similar to findings of Mayberry et al [30], the interviewees in the current study reported
positive family support as one of the important facilitators for OHA adherence. The concept of
involving a role model in interventions that target behaviour change has been effective in
changing physical activity and nutrition behaviours [31]. However, this approach has not been
applied to medication adherence. Nevertheless, some of those interviewed during the current
study believed that acting as a role model inspired other patients with diabetes to adhere to
their medications. Using behaviour change techniques such as modeling using a role model
might facilitate OHA adherence and could be explored further.
The patient-physician relationship is another important social factor raised by the inter-
viewees, wherein a good relationship was reported as a facilitator and vice versa. Good com-
munication between patient and physician increases patient’s confidence as well as their
ability to cope with a chronic illness such as diabetes, thereby improving their medication
adherence [32]. Therefore, appropriate training is needed for health care professionals sup-
porting them to train and use skills to build rapport and engage in patient-centered care with
their patients.
Gaps in knowledge about diabetes and OHAs were among the barriers identified as affect-
ing adherence in this study; the association between appropriate knowledge and good medica-
tion adherence has been shown elsewhere [33]. Over half of our cohort were enrolled in the
5-day specialised education program, offered by the University Diabetes Centre responsible
for their care, yet the interviewees identified knowledge gaps. The "one size fits all" approach
might not be as effective as intended and specific intervention strategies that address individ-
ual patients’ needs should be considered. Additionally, pharmacist-led interventions have
improved patients mediation adherence with diabetes [34] and could be considered as an
adjunct to the support currently offered by the University Diabetes Centre.
Various beliefs about the consequences of diabetes and trying to avoid them were facilita-
tors of OHA adherence. Guenette et al conducted six focus groups with 45 participants with
Type 2 diabetes who had been taking OHM for more than three months and demonstrated
that patients’ willingness to avoid long term complications was the most important factor asso-
ciated with high OHA adherence [28]. Conversely, anticipated side effects are an important
barrier to OHA adherence and have been reported among a wide range of populations [35–
37]. The positive aspect of OHA adherence in improving quality of life should be addressed,
particularly as medication adherence has been associated with enhanced quality of life among
patients with diabetes [38].
Participants’ religious beliefs seemed to influence their OHA adherence. Religious empow-
erment of medication adherence would encourage patients to schedule their diabetes manage-
ment behaviours e.g. taking medications when going to the mosque, church, and temple,
similar to what has been earlier reported by Hatahet al. from Malaysia [39].
Non-adherence to diabetes medication could either be intentional (decision-making) or
un-intentional (forgetfulness) [30]. The current study reported forgetfulness as one of the
unintentional OHA adherence barriers, whilst on the other hand, some interviewees inten-
tionally decided not to adhere to their medication when experiencing side effects or during
stressful events. Intentional non-adherence might explain the mismatch between medication
adherence (MMAS-8) and diabetic control (HbA1c) of some interviewees, where some low
adherent individuals (using MMAS-8) had good diabetic control (using HbA1c). However, as
per the findings of Stack et al [40], unintentional nonadherence to OHAs was high in compari-
son with antihypertensive medications and statins. Therefore, intentional and unintentional
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adherence behaviours should be clearly differentiated among patients with diabetes since each
requires different interventional approaches.
Strengths and limitations
The cross-sectional study did not explore intentional versus un-intentional adherence. Reanal-
ysis of the MMAS-8 to identify these percentages could be undertaken. The MASA interviews
examined the patient perspectives regarding OHA adherence without differentiating between
individuals with low and high adherence. Further analysis could be undertaken to compare
the beliefs of low and high adherence.
MMAS-8 is a measure of self-reported behaviour and as such, outcomes could be biased.
Social desirability bias and giving answers that favoured the behaviour of adherence and over
estimation might have occurred in studies using self-reported measures [41]. However, this
tool has been proven to have good reliability and validity [4]. This is a single centre study, con-
ducted in a tertiary centre, as such, the results might not be generalisable to other patients with
Type 2 diabetes who are cared for by non-tertiary or specialist centres. It is worthy of note,
however, that despite being treated at a tertiary centre and having access to the educational
programme, only 40% of patients in our study achieved high adherence rates.
Conclusion
Low OHA adherence may contribute to the rates of morbidity and mortality observed
amongst patients with Type 2 diabetes in Saudi Arabia. Low adherence is not solely an individ-
ual or patient-related problem. Physician, societal and organizational factors influence this
behaviour, therefore a comprehensive, multi-faceted approach is required to optimise the ben-
efits of OHA medication.
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